MX353623B - Sistema de suministro de farmaco. - Google Patents
Sistema de suministro de farmaco.Info
- Publication number
- MX353623B MX353623B MX2013013204A MX2013013204A MX353623B MX 353623 B MX353623 B MX 353623B MX 2013013204 A MX2013013204 A MX 2013013204A MX 2013013204 A MX2013013204 A MX 2013013204A MX 353623 B MX353623 B MX 353623B
- Authority
- MX
- Mexico
- Prior art keywords
- drug delivery
- delivery system
- active ingredient
- immediate release
- time controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La invención se relaciona con un sistema de suministro de fármaco de liberación inmediata, controlada en tiempo para administración oral de un primer ingrediente activo a un sujeto en necesidad del mismo. La invención adicionalmente se relaciona con un dispositivo de fármaco doble que comprende el sistema de suministro de fármaco de liberación inmediata controlado en tiempo de acuerdo con la invención, que comprende además un segundo recubrimiento que comprende un segundo ingrediente activo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11166091 | 2011-05-13 | ||
EP11181165 | 2011-09-13 | ||
EP11183732 | 2011-10-03 | ||
PCT/NL2012/050336 WO2012158030A2 (en) | 2011-05-13 | 2012-05-14 | Drug delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013013204A MX2013013204A (es) | 2014-06-06 |
MX353623B true MX353623B (es) | 2018-01-22 |
Family
ID=46197660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013204A MX353623B (es) | 2011-05-13 | 2012-05-14 | Sistema de suministro de farmaco. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9763884B2 (es) |
EP (1) | EP2709597A2 (es) |
JP (1) | JP6121990B2 (es) |
KR (2) | KR102158948B1 (es) |
CN (2) | CN103648487B (es) |
AU (1) | AU2012256501B2 (es) |
BR (1) | BR112013029199B1 (es) |
CA (1) | CA2835845C (es) |
EA (1) | EA034288B1 (es) |
IL (1) | IL229425B (es) |
MX (1) | MX353623B (es) |
SG (2) | SG194943A1 (es) |
WO (1) | WO2012158030A2 (es) |
ZA (1) | ZA201309156B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105307645A (zh) * | 2013-06-03 | 2016-02-03 | 麦克内尔股份公司 | 用于在口腔中释放至少一种活性药物成分的固体药物剂型 |
CA2930228A1 (en) | 2013-11-11 | 2015-05-14 | Limoxifen B.V. | Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions |
EP3248592A1 (en) | 2016-05-25 | 2017-11-29 | EB IP Hybritabs B.V. | Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems |
CA3087272A1 (en) | 2017-12-29 | 2019-07-04 | Laxxon Medical Ag | Drug delivery system |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
KR102084602B1 (ko) * | 2018-11-08 | 2020-03-04 | 주식회사 서흥 | 발포성 및 안정성이 향상된 구강 세정용 발포정 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5120720A (en) * | 1990-09-20 | 1992-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
WO1993019741A1 (en) | 1992-03-31 | 1993-10-14 | Benzon Pharma A/S | A pharmaceutical formulation |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
JP3134187B2 (ja) * | 1996-03-07 | 2001-02-13 | 武田薬品工業株式会社 | 放出制御組成物 |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
WO1998027967A1 (en) | 1996-12-20 | 1998-07-02 | Dumex-Alpharma A/S | Release-controlled coated tablets |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
HUP0004945A3 (en) | 1997-10-09 | 2005-03-29 | Perio Prod Ltd | Delayed total release gastrointestinal drug delivery system |
JP4012689B2 (ja) * | 1998-10-01 | 2007-11-21 | ノバルティス アクチエンゲゼルシャフト | 新規徐放性経口製剤 |
US6977083B1 (en) | 1998-10-02 | 2005-12-20 | Jenapharm Gmbh & Co. Kg | Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
SE9902386D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
CA2463687A1 (en) * | 2001-10-18 | 2003-04-24 | Decode Genetics Ehf | Cyclodextrin complexes |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
US20050031688A1 (en) * | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
CN1946376A (zh) * | 2004-03-25 | 2007-04-11 | 布里斯托尔-迈尔斯·斯奎布公司 | 包衣片剂组合物及其制法 |
RU2436579C2 (ru) | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
EP1858493A4 (en) * | 2005-03-14 | 2010-12-01 | Sun Pharmaceutical Ind Ltd | SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS |
FR2883179B1 (fr) * | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
KR20080031037A (ko) * | 2005-06-29 | 2008-04-07 | 와이어쓰 | 결합형 에스트로겐과 바제독시펜의 제형 |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
CN100551373C (zh) | 2005-12-01 | 2009-10-21 | 北京华素制药股份有限公司 | 盐酸丁螺环酮缓/控释微丸 |
WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
GB0606562D0 (en) | 2006-03-31 | 2006-05-10 | Novartis Ag | Organic compounds |
TW200806282A (en) | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
CA2651798C (en) | 2006-05-09 | 2015-07-21 | Mallinckrodt Inc. | Zero-order modified release solid dosage forms |
WO2008008434A1 (en) * | 2006-07-11 | 2008-01-17 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
BRPI0716439B8 (pt) * | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2009098697A1 (en) | 2008-02-08 | 2009-08-13 | Dexxon Ltd. | Modafinil and sildenafil dosage forms |
JP5777273B2 (ja) | 2008-07-10 | 2015-09-09 | 大正製薬株式会社 | 不快な呈味を有する薬物を含有する製剤粒子 |
US9005661B2 (en) | 2009-09-15 | 2015-04-14 | Beijing Team Hospital Management Co., Ltd. | Osmotic pump controlled release tablet and preparation method thereof |
-
2012
- 2012-05-14 KR KR1020197018829A patent/KR102158948B1/ko active IP Right Grant
- 2012-05-14 CN CN201280034770.7A patent/CN103648487B/zh active Active
- 2012-05-14 SG SG2013084132A patent/SG194943A1/en unknown
- 2012-05-14 AU AU2012256501A patent/AU2012256501B2/en active Active
- 2012-05-14 EA EA201391689A patent/EA034288B1/ru not_active IP Right Cessation
- 2012-05-14 KR KR1020137033031A patent/KR20140048882A/ko not_active IP Right Cessation
- 2012-05-14 CA CA2835845A patent/CA2835845C/en active Active
- 2012-05-14 SG SG10201606751XA patent/SG10201606751XA/en unknown
- 2012-05-14 EP EP12724767.4A patent/EP2709597A2/en active Pending
- 2012-05-14 MX MX2013013204A patent/MX353623B/es active IP Right Grant
- 2012-05-14 JP JP2014510273A patent/JP6121990B2/ja active Active
- 2012-05-14 CN CN201910244873.XA patent/CN109908099B/zh active Active
- 2012-05-14 WO PCT/NL2012/050336 patent/WO2012158030A2/en active Application Filing
- 2012-05-14 US US14/117,619 patent/US9763884B2/en active Active
- 2012-05-14 BR BR112013029199-0A patent/BR112013029199B1/pt active IP Right Grant
-
2013
- 2013-11-13 IL IL229425A patent/IL229425B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09156A patent/ZA201309156B/en unknown
-
2017
- 2017-08-25 US US15/687,303 patent/US10966933B2/en active Active
-
2021
- 2021-04-06 US US17/223,124 patent/US20210290551A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013013204A (es) | Sistema de suministro de farmaco. | |
EP3146515A4 (en) | System and method for medicament storage, dispensing, and administration | |
EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
EP2734262A4 (en) | INTRAVAGINAL DEVICES FOR DRUG RELIEF | |
IN2015DN03984A (es) | ||
EP3072506A4 (en) | Carrier for drug delivery and conjugate, composition containing same, and method for administering same | |
AU2012347200A8 (en) | Tablet capable of combatting misuse by injection | |
WO2012174158A3 (en) | Administration of benzodiazepine | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
TN2014000322A1 (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
MY163809A (en) | Transdermal drug delivery system containing donepezil | |
EP2804596B8 (en) | Transmucosal administration system for a pharmaceutical drug | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
AU2013344654A1 (en) | Oral transmucosal drug delivery system | |
HK1215529A1 (zh) | 口腔經粘膜藥物遞送系統 | |
MX2014005270A (es) | Sistema de administracion vaginal con activiad osmotica. | |
IL236757B (en) | A device for administering a drug with retention in the digestive tract | |
CR20140358A (es) | Sistema para la administración de fármacos | |
EP2632902A4 (en) | IMPROVED ORAL ADMINISTRATION OF ORAL DRUG DELIVERY SYSTEM | |
MX2015007731A (es) | Formulacion farmaceutica que comprende ciclesonida. | |
GB201211535D0 (en) | Drug delivery device for simultaneously delivering at least two medicaments | |
GB201211538D0 (en) | Drug delivery device for simultaneously delivering at least two medicaments | |
MX2018010065A (es) | Forma de dosificacion oral que comprende rifaximina en forma beta. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: EB IP HYBRITABS B.V. |
|
FG | Grant or registration |